newsfilter
← Latest News
PR Newswire·

U.S. FDA Approves Nova Mentis Orphan Drug Application

Psilocybin Fragile X Syndrome Treatment VANCOUVER, BC, Nov. 2, 2021 /PRNewswire/ - Nova Mentis Life Science Corp. (CSE:NOVA) (FSE: HN3Q) (OTCQB:NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin